NeOnc Secures UAE IND Approval for NEO100, Expanding CNS Cancer Pipeline
Event summary
- NeOnc received UAE IND approval for NEO100, covering Phase 1-2 adult and pediatric studies in gliomas.
- Approval spans three protocols (NEO100-01, -02, -03) and complements existing FDA designations for NEO100.
- U.S. Phase 2a trial (NEO100-01) fully enrolled; top-line data expected by late July 2026.
- NEO100 is an intranasal perillyl alcohol formulation targeting recurrent Grade III/IV gliomas.
The big picture
NeOnc’s UAE IND approval for NEO100 strengthens its position in CNS oncology, where blood-brain barrier challenges limit treatment options. The move complements its FDA-designated pipeline and aligns with broader industry shifts toward non-invasive brain cancer therapies. With Phase 2a data looming, the company is poised to either validate its intranasal delivery platform or face pivotal regulatory crossroads.
What we're watching
- Regulatory Pathways
- Whether Phase 2a data supports Breakthrough Therapy designation or accelerates U.S. development.
- Pediatric Expansion
- The pace at which NEO100 advances into pediatric glioma trials under UAE authorization.
- Global Strategy
- How NeOnc balances parallel development in the U.S. and UAE amid upcoming data readouts.
Related topics